A share price of Day One Biopharmaceuticals Inc [DAWN] is currently trading at $17.38, up 11.05%. An important factor to consider is whether the stock is rising or falling in short-term value. The DAWN shares have gain 16.72% over the last week, with a monthly amount glided 22.31%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress. In a post published today on Yahoo Finance, PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024.
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on April 25, 2023, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $9 from $34. Previously, CapitalOne started tracking the stock with Overweight rating on February 08, 2023, and set its price target to $40. On February 03, 2023, Oppenheimer initiated with a Perform rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $35 on December 15, 2022. Needham initiated its recommendation with a Buy and recommended $40 as its price target on December 14, 2022. Goldman started tracking with a Buy rating for this stock on December 05, 2022, and assigned it a price target of $45. In a note dated December 01, 2022, BofA Securities initiated an Buy rating and provided a target price of $34 on this stock.
Day One Biopharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $9.67 and $20.39. Currently, Wall Street analysts expect the stock to reach $41.25 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $17.38 at the most recent close of the market. An investor can expect a potential return of 137.34% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.07 points at the first support level, and at 14.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.10, and for the 2nd resistance point, it is at 18.81.
Day One Biopharmaceuticals Inc [DAWN] reported earnings per share of -$0.54 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.6/share, meaning a difference of $0.06 and a surprise factor of 10.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.61 per share as compared to estimates of -$0.61 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Day One Biopharmaceuticals Inc [NASDAQ:DAWN] is 12.72. On the other hand, the Quick Ratio is 12.72, and the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Bender Jeremy, CHIEF EXECUTIVE OFFICER, that happened on Feb 16 when 7615.0 shares were sold. GENERAL COUNSEL, Dubow Adam completed a deal on Feb 16 to sell 3242.0 shares. Meanwhile, COO, CFO AND SECRETARY York Charles N II sold 2666.0 shares on Feb 16.
